基于流式细胞术的白血病细胞富集联合突变分析实现急性髓系白血病敏感且广泛适用的残留病检测
该研究将靶向CLL-1、TIM-3、CD123和CD117的流式细胞术白血病细胞富集与突变分析结合,用于急性髓系白血病可测量残留病检测。稀释实验显示灵敏度达10^-4至10^-5,41例缓解样本中39例富集后DNA足以进行突变分析,中位随访559天,MRD阳性者71.4%复发而MRD阴性者27.8%复发(P = .007)。
要点
- 联合抗体富集后突变分析检测MRD灵敏度达10^-4至10^-5。
- 41例缓解样本中39例富集后DNA质量满足NGS或数字PCR分析。
- 中位随访559天,MRD阳性者复发率71.4%高于MRD阴性者27.8%(P = .007)。
核心结论
- 基于CLL-1、TIM-3、CD123和CD117抗体的流式细胞术白血病细胞富集联合突变分析可实现高灵敏度MRD检测,并对多数急性髓系白血病患者的复发风险有提示意义。
研究设计与样本
- 研究采用流式细胞术白血病细胞富集联合复发性突变基因分析的方法学,稀释实验评估灵敏度,并前瞻性收集缓解样本进行验证。
- 缓解样本共41例,其中39例富集后DNA质量满足下一代测序或数字PCR突变分析。
主要发现
- 稀释实验中该方法检测残留病的灵敏度为10^-4至10^-5。
- 前瞻性缓解样本中该标记组合实现中位67倍细胞富集,41例中39例DNA质量满足下一代测序或数字PCR突变分析。
- 41例样本中21例(53.8%)检测为MRD阳性,18例(46.2%)为阴性。
- 中位随访559天,MRD阳性患者71.4%(15/21)复发 vs MRD阴性患者27.8%(5/18)复发(P = .007)。
- MRD阳性患者累积复发率更高(5年累积复发率:90.5% vs 28%,P < .001),多因素分析中MRD阳性为累积复发率的重要影响因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistent measurable residual disease (MRD) is an increasingly important prognostic marker in acute myeloid leukemia (AML). Currently, MRD is determined by multi-parameter flow cytometry (MFC) or PCR-based methods detecting leukemia-specific fusion transcripts and mutations. However, while MFC is highly operator-dependent and difficult to standardize, PCR-based methods are only available for a minority of AML patients. Here we describe a novel, highly sensitive and broadly applicable method for MRD detection by combining MFC-based leukemic cell enrichment using an optimized combinatorial antibody panel targeting CLL-1, TIM-3, CD123 and CD117, followed by mutational analysis of recurrently mutated genes in AML. In dilution experiments this method showed a sensitivity of 10-4 to 10-5 for residual disease detection. In prospectively collected remission samples this marker combination allowed for a median 67-fold cell enrichment with sufficient DNA quality for mutational analysis using next generation sequencing (NGS) or digital PCR in 39 out of 41 patients. Twenty-one samples (53.8%) tested MRD positive, whereas 18 (46.2%) were negative. With a median follow-up of 559 days, 71.4% of MRD positive (15/21) and 27.8% (5/18) of MRD negative patients relapsed (P = .007). The cumulative incidence of relapse (CIR) was higher for MRD positive patients (5-year CIR: 90.5% vs 28%, P < .001). In multivariate analysis, MRD positivity was a prominent factor for CIR. Thus, MFC-based leukemic cell enrichment using antibodies against CLL-1, TIM-3, CD123 and CD117 followed by mutational analysis allows high sensitive MRD detection and is informative on relapse risk in the majority of AML patients.
引用
- Daga S, Rosenberger A, Kashofer K, et al. Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. Am J Hematol. 2020. PMID: 32602117. doi:10.1002/ajh.25918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。